work
highli
pathogen
materi
mandat
use
biolog
contain
facil
involv
microbiolog
safeti
cabinet
specialist
laboratori
engin
structur
typifi
contain
level
laboratori
consequ
work
high
contain
practic
difficulti
associ
contain
specialist
assay
equip
often
essenti
experiment
analys
era
increas
interest
biodef
pathogen
emerg
diseas
immunolog
analysi
develop
rapidli
alongsid
tradit
techniqu
virolog
molecular
biolog
exampl
order
maximis
use
small
sampl
volum
multiplex
becom
popular
widespread
approach
quantifi
multipl
analyt
simultan
cytokin
chemokin
luminex
microspher
system
allow
detect
mani
cytokin
chemokin
singl
sampl
detect
method
use
align
laser
fluidic
mean
sampl
often
analys
low
contain
facil
order
perform
cytokin
analysi
materi
high
contain
laboratori
develop
appropri
inactiv
methodolog
stain
step
although
result
reduct
median
fluoresc
intens
produc
statist
compar
outcom
judg
noninactiv
sampl
methodolog
thu
extend
use
luminex
technolog
materi
contain
highli
pathogen
biolog
agent
determin
level
cytokin
produc
infecti
diseas
aid
interpret
pathogen
mechan
identifi
potenti
area
clinic
therapeut
intervent
particular
interest
work
identif
understand
flux
cytokin
chemokin
produc
infect
virus
caus
haemorrhag
fever
human
mani
virus
thought
target
infect
cell
innat
immun
system
macrophag
dendrit
cell
result
releas
proinflammatori
cytokin
chemokin
review
bray
highli
pathogen
microorgan
studi
ebola
viru
receiv
major
share
attent
part
due
sampl
investig
outbreak
also
due
avail
suitabl
anim
model
high
contain
facil
usa
thu
human
ebola
infect
level
interleukin
il
interferon
ifn
tumour
necrosi
factor
tnf
protein
ip
macrophag
inflammatori
protein
mip
rant
regul
activ
normal
cellexpress
secret
monitor
show
differ
level
compar
control
patient
well
survivor
nonsurvivor
hutchinson
rollin
addit
cytokin
level
granulocyt
macrophag
colonystimul
factor
gmcsf
monocyt
chemoattract
protein
mcp
assess
ebolainfect
cynomolgu
macaqu
hutchinson
et
al
mani
cytokin
chemokin
potenti
involv
pathogenesi
viral
haemorrhag
fever
abil
use
multiplex
assay
simultan
assess
numer
sampl
extrem
benefici
applic
also
extend
determin
respons
postvaccin
drug
therapi
especi
assess
novel
intervent
work
highli
pathogen
materi
possibl
perform
downstream
assay
work
high
contain
laboratori
inactiv
infecti
materi
use
gamma
irradi
current
practic
downstream
assay
work
difficult
uk
due
regulatori
histori
work
contain
pathogen
biolog
safeti
cabinet
therebi
use
concept
primari
contain
ii
consequenti
lack
amen
facil
includ
readi
access
irradi
equip
addit
avail
contain
luminex
reader
present
difficulti
unknown
risk
use
align
laser
within
microbiolog
safeti
cabinet
unclear
impact
subsequ
treatment
formaldehyd
vapour
cabinet
decontamin
procedur
thu
investig
role
mani
immunolog
process
associ
pathogenesi
agent
requir
high
contain
viral
haemorrhag
fever
infect
necessit
appropri
form
sampl
inactiv
measur
made
one
simpl
wide
use
method
erad
viru
infect
sampl
heat
inactiv
often
use
subsequ
test
requir
antibodi
detect
although
mani
virus
includ
viral
haemorrhag
fever
lassa
ebola
marburg
inactiv
heat
min
mitchel
mccormick
cytokin
prone
heat
degrad
condit
altern
allow
measur
factor
clinic
sampl
requir
irradi
use
gamma
ray
approxim
rad
suitabl
altern
use
measur
cytokin
use
multiplex
luminex
analysi
hutchinson
rollin
howev
facil
irradi
wide
avail
effici
treatment
depend
viral
genom
size
sera
concentr
temperatur
inactiv
mahanti
et
al
chemic
inactiv
viru
infect
formalin
anoth
simpl
routin
use
method
unfortun
treatment
alter
cytokin
chemokin
protein
detect
immunoassay
impair
mahanti
et
al
work
investig
whether
would
possibl
employ
simpl
routin
chemic
inactiv
sampl
cytokinechemokin
antibodi
bind
detector
molecul
use
readout
would
possibl
outsid
high
contain
employ
use
luminex
microbead
sampl
high
contain
develop
standard
stain
procedur
condit
follow
inactivationfix
step
use
formalin
treatment
compar
detect
molecul
without
formalin
fixat
present
statist
signific
data
illustr
util
methodolog
studi
high
contain
pathogen
heparinis
blood
collect
seven
healthi
uk
volunt
blood
dilut
ratio
rpmi
media
sigmaaldrich
dorset
uk
supplement
mm
lglutamin
sigmaaldrich
uml
penicillin
plu
streptomycin
sigmaaldrich
ml
dilut
blood
ad
tube
along
ngml
phorbol
pma
sigmaaldrich
ngml
ionomycin
sigmaaldrich
phytohemagglutinin
pha
sigmaaldrich
lipopolysaccharid
lp
sigmaaldrich
sampl
incub
co
incub
cell
harvest
h
pma
ionomycin
day
pha
lp
centrifug
g
min
collect
supernat
sampl
store
requir
analysi
commerci
human
luminex
kit
use
studi
millipor
watford
uk
assay
perform
accord
manufactur
instruct
briefli
well
filter
membran
microtit
plate
prewet
assay
buffer
sampl
standard
qualiti
control
prepar
ad
relev
well
incub
premix
microbead
h
orbit
plate
shaker
room
temperatur
plate
wash
twice
assay
wash
buffer
biotinyl
detector
antibodi
ad
per
well
sampl
incub
h
room
temperatur
plate
shaker
without
wash
streptavidinphycoerythrin
solut
ad
plate
incub
min
room
temperatur
plate
shaker
protect
direct
light
complet
stain
microbead
wash
twice
assay
wash
buffer
bead
left
overnight
h
formalin
formalin
phosphat
buffer
salin
pb
solut
formalin
made
dilut
formalin
wv
formaldehyd
solut
scientif
laboratori
suppli
nottingham
england
pb
formalin
made
dilut
analyz
microbead
wash
twice
assay
wash
buffer
resuspend
luminex
sheath
fluid
luminex
assay
acquir
instrument
use
expon
softwar
invitrogen
paisley
england
acquisit
gate
set
discrimin
doublet
event
ensur
singl
microbead
measur
event
per
region
collect
median
fluoresc
intens
mfi
measur
mfi
convert
concentr
use
result
standard
cytokin
prepar
cytokin
standard
dilut
start
concentr
pgml
give
lower
limit
detect
pgml
statist
analysi
carri
use
minitab
statist
softwar
version
compar
result
treatment
data
screen
normal
use
andersondarl
test
data
normal
distribut
pair
ttest
use
data
normal
distribut
nonparametr
mannwhitney
statist
test
use
signific
valu
pb
appli
test
two
qualiti
control
prepar
suppli
luminex
kit
expect
rang
cytokin
pgml
respect
cytokin
level
assess
microbead
use
sampl
rang
similar
control
sampl
pb
alon
formalin
treat
formalin
solut
fig
result
cytokin
compar
individu
vs
formalin
vs
formalin
signific
differ
observ
mannwhitney
statist
test
p
n
result
show
formalin
treatment
stain
significantli
affect
determin
cytokin
concentr
observ
treatment
formalin
solut
mfi
read
reduc
cytokin
test
exampl
result
standard
prepar
pgml
shown
fig
effect
seen
prepar
test
result
significantli
differ
pair
ttest
p
b
formalin
concentr
compar
untreat
sampl
determin
whether
formalin
treatment
affect
measur
clinic
sampl
human
blood
stimul
mitogen
prepar
concentr
cytokin
chemokin
mitogenstimul
human
pbmc
shown
tabl
show
variat
level
produc
condit
without
treatment
formalin
solut
concentr
formalin
treatment
compar
untreat
sampl
determin
whether
inactiv
detriment
effect
major
cytokin
test
show
formalin
inactiv
significantli
affect
yield
compar
untreat
sampl
fig
except
formalin
formalin
formalin
formalin
differ
reach
signific
mannwhitney
statist
test
p
b
result
present
report
provid
evid
luminex
assay
carri
infecti
materi
laboratori
treatment
microbead
formalin
solut
poststain
formalin
alter
physic
properti
microbead
colorimetr
dye
ratio
use
identifi
individu
bead
set
data
shown
enabl
data
acquisit
analyz
use
normal
methodolog
set
bead
region
given
supplier
observ
formalin
treatment
significantli
alter
mfi
read
reduc
intens
measur
observ
also
seen
flow
cytometri
protocol
formalin
inactiv
reduc
mfi
cell
fix
prior
mae
et
al
mccarthi
et
al
stain
fluoresc
antibodi
effect
photobleach
formalin
also
note
cell
fix
mount
immunofluoresc
slide
methodolog
canet
et
al
author
latter
report
suggest
oxygenscaveng
solut
may
reduc
bleach
effect
fluoresc
probe
howev
reduc
mfi
littl
effect
concentr
cytokin
detect
use
differ
suspens
increas
mfi
formalin
fix
sampl
address
result
report
show
treat
stain
microbead
formalin
solut
significantli
affect
measur
cytokin
test
knowledg
first
report
show
formaldehyd
fixat
luminex
microbead
prior
stain
due
constraint
work
within
enclos
microbiolog
safeti
cabinet
complex
luminex
analys
stain
plate
undertaken
within
contain
without
complic
howev
read
result
need
perform
within
lower
contain
facil
treat
bead
formalin
overnight
allow
inactiv
pathogen
materi
also
sterilis
plate
surfac
analysi
outsid
contain
eg
fumig
formaldehyd
vapour
improv
previou
report
use
paraformaldehyd
solut
inactiv
quantifi
cytokin
level
detriment
effect
yield
compar
untreat
sampl
mahanti
et
al
investig
effect
human
sampl
pbmc
stimul
pma
ionomycin
pha
lp
h
h
respect
untreat
sampl
result
variat
cytokinechemokin
yield
mitogen
treatment
also
howev
differ
would
also
expect
natur
occur
given
cytokin
secret
equal
addit
one
mitogen
treatment
sometim
result
preferenti
higher
level
howev
enhanc
data
allow
breadth
respons
compar
tabl
concentr
pgml
cytokineschemokin
mitogenstimul
pbmc
without
formalin
treatment
formalin
treatment
experiment
need
like
measur
flux
level
cytokineschemokin
heterogen
data
add
confid
observ
applic
futur
studi
cytokin
show
differ
formalin
treatment
one
differ
concentr
wherea
remain
three
nonsignific
use
formalin
result
suggest
use
higher
concentr
formalin
result
cytokin
statist
differ
untreat
sampl
observ
compar
studi
inflammatori
cytokin
measur
luminex
analysi
supernat
inactiv
paraformaldehyd
prior
microbead
stain
result
show
two
cytokin
five
display
respons
detect
paraformaldehydetr
sampl
use
concentr
mahanti
et
al
addit
use
paraformaldehyd
fixat
fluoresc
situ
hybridis
result
cell
greater
stabil
integr
time
fixat
paraformaldehyd
murrellbussel
et
al
therefor
higher
concentr
formalin
could
lead
increas
stabil
microbead
bound
cytokin
detector
antibodi
howev
futur
work
differ
level
formalin
solut
warrant
investig
observ
concentr
formalin
use
analysi
formaldehyd
formaldehyd
shown
concentr
low
formalin
complet
inactiv
filovirus
ebola
marburg
within
hour
exposur
kuhn
treatment
formaldehyd
solut
report
effect
wide
rang
virus
use
facil
includ
coronaviru
induc
sever
acut
respiratori
syndrom
sar
darnel
et
al
hantaan
viru
krau
et
al
concentr
formaldehyd
respect
addit
formaldehyd
proven
effici
inactiv
bacteria
includ
mycobacterium
tuberculosi
schwebach
et
al
well
use
human
sampl
fact
luminex
analysi
routin
avail
nonhuman
primat
materi
giavedoni
allow
test
paramet
use
assay
import
anim
model
care
exercis
treatment
formalin
suffici
deactiv
agent
handl
oper
laboratori
despit
vv
formaldehyd
use
inactiv
human
immunodefici
viru
hiv
lifson
et
al
temperatur
also
exert
critic
effect
exampl
use
paraformaldehyd
solut
shown
h
incub
hiv
still
detect
incub
viru
inactiv
within
h
aloisio
nicholson
report
formalin
inactiv
carri
room
temperatur
purpos
mimic
overnight
formaldehyd
fumig
within
microbiolog
safeti
cabinet
temperatur
difficult
standardis
chemic
method
viral
inactiv
report
includ
use
logrippo
hartman
acet
acid
mitchel
mccormick
aziridin
brown
howev
formaldehyd
treatment
wide
use
test
mani
laboratori
inactiv
highli
pathogen
virus
use
better
standardis
proven
summari
describ
effici
method
inactiv
luminex
bead
allow
simultan
quantif
multipl
cytokin
chemokin
sampl
requir
handl
high
biolog
contain
facil
work
may
help
elucid
mechan
pathogenesi
virus
provid
approach
multiplex
assay
thu
ensur
maxim
use
made
sampl
avail
facil
acknowledg
work
form
import
proofofprincip
studi
work
may
requir
includ
carri
work
within
class
iii
microbiolog
safeti
cabinet
